Micro Therapeutics Receives $3.7 Million Payment

Micro Therapeutics Receives $3.7 Million Payment 


IRVINE, Calif., Feb. 1  /PRNewswire-FirstCall/ -- Micro Therapeutics, Inc.
(MTI) (NASDAQ:MTIX) today said that it has received a $3.7 million payment
resulting from the acquisition of certain assets of Genyx Medical, Inc., a
company in which MTI held a minority equity interest, by C. R. Bard Inc.
(NYSE:BCR).  Genyx, a privately held company based in Aliso Viejo, CA, licensed
MTI's proprietary liquid embolic technology for certain non-vascular
applications in 1997.  Genyx recently announced that it had received FDA
approval for URYX(R), an injectable tissue bulking agent for the treatment of
stress urinary incontinence that is based on the technology licensed from MTI.

About Micro Therapeutics, Inc.

MTI develops, manufactures and markets minimally invasive medical devices for
the diagnosis and treatment of vascular disorders.  The company's primary focus
is on catheter based technologies and products for the interventional
neuroradiology market.  MTI's products include the Sapphire(R) and NXT lines of
embolic coils, the ONYX(R) liquid embolic system, and a broad line of micro
catheters, guidewires, and occlusion balloons that are utilized in the
treatment of cerebral vascular disorders. 

DATASOURCE: Micro Therapeutics, Inc.



CONTACT:  Thomas C. Wilder of Micro Therapeutics, Inc., [phone];

or Rob Whetstone or Robert Jaffe, both of PondelWilkinson Inc.,

[phone], for Micro Therapeutics, Inc.

Copyright